Daraxonrasib for Previously Treated RAS -Mutant Non–Small-Cell Lung Cancer

Live updates

1. 4d ago

   FDA Approves Rasonque as Daraxonrasib Shows Promise for Lung Cancer

   The FDA approved Rasonque in August 2026, a drug also known as daraxonrasib. While the medication is already authorized for metastatic pancreatic cancer, early trials indicate it may effectively treat lung cancer in patients who do not respond to standard therapies. Clinical results involving patients at the Memorial Sloan Kettering Cancer Center have been released to evaluate the drug's efficacy for RAS-mutant non-small-cell lung cancer. Access remains a concern due to high costs associated with advanced oncology treatments.

   Why it matters

   RAS-mutant non-small-cell lung cancer often resists standard care, creating a need for targeted therapies. Daraxonrasib represents a potential shift in treatment for this specific mutation. The drug's transition from pancreatic cancer use to lung cancer applications expands its clinical utility.

   What is confirmed

   • The FDA approved Rasonque in August 2026.
   • Daraxonrasib is the same drug as Rasonque.
   • The medication is approved for the treatment of metastatic pancreatic cancer.
   • Early trials show daraxonrasib may help treat lung cancer.

   Still unconfirmed

   • Clinical results for patients not responding to standard treatment were released via Memorial Sloan Kettering Cancer Center.
   • The drug marks a new era for RAS-mutated lung cancer.

   What to watch next

   • Publication of full Phase 3 data for lung cancer indications.
   • FDA decision on expanding the approved label of Rasonque to include non-small-cell lung cancer.
   Sources used for this update (5)

   1. finance.yahoo.com — What Price Healthcare? RevMed’s Rasonque-The US Drug Pricing Paradox
   2. www.pharmnews.com — "도세탁셀 넘나"...RAS 변이 폐암 후보물질 '다락손라시브' 유효성 확인
   3. oncodaily.com — Salman Punekar: Daraxonrasib Marks a New Era for RAS-Mutated Lung Cancer
   4. www.rttnews.com — New FDA Drug Approvals - August 2026
   5. www.medicalnewstoday.com — Pancreatic cancer drug may also help fight treatment-resistant lung cancer
   confidence 90%
2. 9d ago

   Daraxonrasib Tested for Previously Treated RAS-Mutant NSCLC

   Researchers are evaluating daraxonrasib for patients with previously treated RAS-mutant non-small-cell lung cancer. The drug, which the FDA approved for pancreatic cancer to improve survival, is now being studied for its potential efficacy in lung cancer. A related medication from RevMed, Rasonque, has also received approval and may be viable for non-small cell lung cancer. Some of these advanced cancer treatments carry high costs, with one pill priced at $480,000 per year.

   Why it matters

   RAS mutations are common drivers in various cancers, making targeted inhibitors critical for patients who fail initial therapies. Expanding a pancreatic cancer drug to lung cancer applications could provide new options for resistant tumors.

   What is confirmed

   • The FDA approved a pancreatic cancer drug that improves survival.
   • Daraxonrasib is being used for previously treated RAS-mutant non-small-cell lung cancer.

   Still unconfirmed

   • RevMed's Rasonque could be effective in non-small cell lung cancer.

   What to watch next

   • Clinical trial results for daraxonrasib in non-small-cell lung cancer populations.
   • FDA approval status for Rasonque in lung cancer indications.
   Sources used for this update (5)

   1. The New York Times — A $480,000-a-Year Pill Reflects a New Normal for Cancer Drugs
   2. ABC News - Breaking News, Latest News and Videos — Pancreatic cancer drug may hold promise for lung cancer as well, early study suggests
   3. BioSpace — RevMed’s newly approved Rasonque could ‘hold up’ in non-small cell lung cancer
   4. The New England Journal of Medicine — Daraxonrasib for Previously Treated RAS -Mutant Non–Small-Cell Lung Cancer
   5. wusa9.com — FDA approves landmark pancreatic cancer drug that's shown to improve survival
   confidence 90%